Datasets (31,150)

mRNA profiling after knockdown of lncRNA Cyrano

Transcriptional response of fibronectin fragment treatment in human articular chondrocytes

RNA-Seq of Human iPSC-cardiomyocytes infected with SARS-CoV-2

IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [METTL KD in PANC-1 (polyA RNA)]

IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in PANC-1 (total RNA)]

IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [E2F1-3 KD in PANC-1 (polyA RNA)]

IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in MV3 (total RNA)]

IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in HepG2 (polyA RNA)]

IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KD in A549 (polyA RNA)]

IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression hallmark in cancer [IGF2BP1 KO in A-549 (polyA RNA)]

Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734

Transcriptomic Characterization of LIPA+/+ and LIPA-/- iPSC-derived Macrophages

Transcriptional profiles of human mature B cells from tonsil tissue

Selective therapeutic targeting of the first and second bromodomains of the BET proteins in cancer and immuno-inflammation [SLAM-seq]

Selective therapeutic targeting of the first and second bromodomains of the BET proteins in cancer and immuno-inflammation [RNA-seq]